Universe Pharmaceuticals INC Reports Fiscal Year 2021 Financial Results
Ji’an, Jiangxi, China, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and...
Day: January 31, 2022
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
PALO ALTO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"),...
Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announced the appointment of...
Medexus Schedules Third Quarter Fiscal 2022 Conference Call
TORONTO and CHICAGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF)...
Spectral Medical Announces U.S. FDA Approval of DIMI Trial Protocol Amendment
Amendment expected to overcome key pandemic challenges and improve both site and patient enrollmentTORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) --...
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services
Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the...
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer
• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part...
BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS™ for the Treatment of OCD
Palmetto GBA Covers Medicare Patients in Seven StatesBURLINGTON, Mass. and JERUSALEM, Jan. 31, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ...
Quipt Announces Revocation of Management Cease Trade Order
CINCINNATI, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based...
Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios
– Outcomes of first eight compassionate use cases presented at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society...
Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner...
InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting App
InteliSwab test With less than one minute of “hands-on time,” the InteliSwab test is as simple as “Swab, Swirl, and...
Jushi Holdings Inc. Launches Investor Video Update Series
Innovative series to highlight Jushi’s leading operational footprint, national expansion plans, and M&A strategy BOCA RATON, Fla., Jan. 31, 2022...
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: Was...
XORTX Provides Corporate Update
Synopsis of 2021 Achievements and Key Activities for 2022CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX"...
Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
Preliminary top line data anticipated throughout 2022HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage...
Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11
Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February...
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) --...
Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing...
